Review consistency
Support a repeatable approach to evaluating relevant audit-trail events.
Purpose-built digital technology for pharmaceutical quality teams. Meet AuditLens — designed to bring structure, traceability and clarity to electronic audit-trail review.
Pre-commercial evaluation · Early demonstrations targeted for November 2026
QualityAdmit is an emerging pharmaceutical software brand informed by more than 15 years of practical experience in pharmaceutical quality control and regulated laboratory workflows.
Our aim is to develop clear, controlled digital tools that support review consistency, accountability and quality decision-making.
Support a repeatable approach to evaluating relevant audit-trail events.
Clarify reviewer, QA and master-rule ownership responsibilities.
Document event assessment and the rationale for review decisions.
Our development priorities include access controls, traceability, verification, and practical quality workflows. Formal validation and customer-specific qualification remain essential before regulated use.
Read our security and compliance approach ↗Share a concise product introduction with your quality and laboratory teams.
For pharmaceutical quality teams, laboratories and potential technology partners.
Tell us about your interest. During this preview stage, the inquiry form opens a pre-filled email rather than sending data to a server.
Request a Demo ↗Large volumes of electronic activity can complicate consistent, risk-based review.
Quality decisions benefit from documented reasoning, not simply a list of events.
Clear roles and review status help teams understand responsibilities and next actions.
Define batch-level or system-level audit-trail review scope.
Evaluate events against configured criteria and record applicable results.
Support reviewer evaluation and documented rationale.
Support quality oversight and controlled review outcomes.
Workflow illustration, not a claim that every feature has completed integration testing or validation.
Controlled review logic aligned to organizational procedures, with designated QA ownership.
Separate responsibilities for reviewers, QA and authorized master-rule users.
Batch and system selection inputs intended to support relevant review coverage.
Traceability of selection, assessment and decision activities, subject to ongoing verification.
Read-only Waters Empower connectivity is a planned integration, not a completed or qualified production connector. Future deployment approaches may include customer-controlled on-premises environments and appropriately secured cloud hosting.
Not yet. It is in pre-commercial development and evaluation; demonstrations are planned subject to readiness.
Read-only Empower integration is planned. It is not currently represented as a verified, production-ready connector.
No FDA approval or validation claim is made. Product testing and formal validation work remain to be completed. Customers must assess qualification and intended-use requirements.
The product is designed around configurable, controlled review criteria. Actual behavior and permissions must be demonstrated and verified in the evaluated build.
Both are potential future options. Availability will depend on technical readiness, security evaluation and deployment qualification.
Role-based permissions and separation of duties for reviewers, QA decision makers and master-rule owners.
Review history and documented rationale to support understanding of decisions.
Rule governance, versioning and approvals are design requirements subject to verification.
Planned read-only acquisition from chromatography data systems where feasible and appropriate.
Risk-based testing and formal validation evidence must precede claims of regulated readiness.
Intended use, SOPs, training, infrastructure and customer qualification require site-specific assessment.
Our product design considers topics commonly associated with 21 CFR Part 11, EU GMP Annex 11 and ALCOA+ data-integrity principles. These references describe design considerations and do not imply endorsement, certification or compliance verification.
Overview of the challenge, intended review workflow, product status and early demonstration opportunity.
Download PDF ↓Our emerging pharmaceutical software brand, purpose and background.
Download PDF ↓How structured review criteria can support more focused event evaluation.
ARTICLE PLANNEDPractical considerations for controlled electronic records and review accountability.
ARTICLE PLANNEDWhy assessment rationale and clear quality oversight matter.
ARTICLE PLANNEDThese are planned editorial topics, not published articles.
Complete the form to prepare an email in your own email application. No information is uploaded or stored by this preview website.
Prefer to contact us directly? contact@qualityadmit.com (pending activation)
The demo inquiry form in this preview prepares an email in your device's email application. The preview website does not submit the form to a QualityAdmit server or maintain a database of submissions. If you send the email, your email provider and the receiving mailbox process the message.
Business inquiries may be used to respond to questions, discuss potential demonstrations or partnerships, and follow up on the requested communication. Specific practices and retention arrangements must be finalized before launch.
This preview uses no analytics or advertising trackers intentionally. External font loading may contact the font provider if the browser is online. Hosting providers may maintain ordinary technical access logs once the website is published.
Do not submit confidential laboratory records, patient information, passwords or sensitive company data through the contact form or email. Privacy-related inquiries can be directed to the future business contact mailbox after it is configured.
Draft prepared October 2026 · Publication pending legal review.